Niguldipine
 | |
| Names | |
|---|---|
| IUPAC name 3-3-(4,4-Diphenyl-1-piperidyl)propyl 5-methyl 2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate | |
| Identifiers | |
CAS Number |
|
3D model (JSmol) |
|
| ChEMBL |
|
| ChemSpider |
|
PubChem CID |
|
| UNII |
|
CompTox Dashboard (EPA) |
|
InChI
| |
| |
| Properties | |
Chemical formula | C36H39N3O6 |
| Molar mass | 609.71136 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).  N verify (what is  Y N ?) Infobox references | |
Chemical compound
Niguldipine is a calcium channel blocker and α1-adrenergic receptor antagonist.[1]
References
- ^ Boer R, Grassegger A, Schudt C, Glossmann H (May 1989). "(+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors". European Journal of Pharmacology. 172 (2): 131–45. doi:10.1016/0922-4106(89)90004-7. PMID 2548881.
- v
- t
- e
(antagonize α-adrenergic
vasoconstriction)
| Central |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peripheral |
|
| Serotonin receptor antagonists | |
|---|---|
| Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
